Early studies evaluating role of immune infiltrate in colorectal cancer

Slides:



Advertisements
Similar presentations
October 23, 2014 John C. Lin, M.D. Ph.D. Vice President, Experimental Medicine Rational Combination of Immunotherapies in Preclinical Cancer Models.
Advertisements

Individualizing Therapy for Gastrointestinal Malignancies 2010 Update
West Midlands Regional Genetics Laboratory
Enhancement Of T-Cell Immunity To Osteosarcoma By Modulation Of Programmed Death Receptor Pathway Pooja Hingorani, Danielle Lussier, Joseph Blattman.
Cancer vaccines are biological response modifiers. They prime the immune system to attack the cancer cells in the body. The goal is to prevent or to treat.
Advanced Cancer Topics Journal Review 4/16/2009 AD.
Featured Poster Abstract 84: CD8 T cell-mediated immune responses are critical to the increased efficacy of Doxil in BRCA1 deficient tumors Gina Mantia-Smaldone,
Bevacizumab continuation versus no continuation after first-line chemo-bevacizumab therapy in patients with metastatic colorectal cancer: a randomized.
Gene Therapy Clinical Trials. Cancer Gene Therapy Three Basic Approaches. Genetically alter a person's immune cells that are already naturally targeted.
SEREX Screening for Colorectal Cancer Antigens Jennifer Newton, MD April 5, 2011 Research Presentation.
Response, PFS or OS – what is the best endpoint in advanced colorectal cancer? Marc Buyse IDDI, Louvain-la-Neuve & Hasselt University
Presented By Michael Overman at 2016 ASCO Annual Meeting
Randomized phase III trial of gemcitabine and cisplatin vs. gemcitabine alone inpatients with advanced non-small cell lung cancer and a performance status.
Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology
West Midlands Regional Genetics Laboratory
Prognostic Factors for First-line Chemotherapy + Bevacizumab or Cetuximab in Metastatic Colorectal Cancer CCO Independent Conference Highlights* of the.
Fig. 1 GBM TIMs expand to inhibit vaccine-induced T-cell mediated tumor cytolysis via PD-1/PD-L1 regulatory pathway. (A, D) CD163, DAPI, (B, E) PD-L1,
University of Southern California, Norris Comprehensive Cancer Center
Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
GENE THERAPY: A brief overview
Franck Housseau PharmD, PhD
Selinexor combines with immune checkpoint blockade to slow B16F10 melanoma tumor growth. Selinexor combines with immune checkpoint blockade to slow B16F10.
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States and data.
The Immune System. The Immune System Adaptive Immune Response.
A Paradigm Shift From One-Size-Fits-All to Tailor-Made Therapy for Metastatic Colorectal Cancer.
What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC
New Patient Journeys in Non-small cell lung cancer
Discussion Outline Cells of the Immune System.
Essential Concepts in Harnessing the Immune System in Head and Neck Cancer.
Tumor Immunology Ali Al Khader, MD Faculty of Medicine
Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?
CDK4/6 Inhibitors in Breast Cancer:
Presented By Johanna Bendell at 2016 ASCO Annual Meeting
Emerging Frontline Treatments for Patients With Hodgkin Lymphoma
PD-1 and LAG-3 expression in MSI and MSS colorectal cancer specimens.
Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating lymphocytes. Geographic distribution in situ of MSI and MSS colorectal cancer–infiltrating.
Frequencies of immune cell types show much stronger variations between tumor types in the tumor infiltrate compared with the spleen and tumor-draining.
Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.
Ajay Goel, Takeshi Nagasaka, Jennifer Spiegel, Richard Meyer, Warren E
Low-dose cyclophosphamide (Cy) reduces intratumoral Treg numbers and promotes enhanced T-cell trafficking and activation within the tertiary lymphoid aggregates.
Changing the Paradigm of Treatment in Patients With Hodgkin Lymphoma
Targeting T Cell Co-receptors for Cancer Therapy
Progression-Free Survival Times Overall Survival Times
Lung Cancer: A Wily Genetic Opponent
Preparing for Checkpoint Inhibitors in Breast Cancer
Cetuximab with chemotherapy as 1st-line treatment for metastatic colorectal cancer: a meta-analysis of the CRYSTAL and OPUS studies according to KRAS.
Targeted Therapies for Hepatocellular Carcinoma
1 Sunnybrook Odette Cancer Centre, University of Toronto, Canada
Checkpoint Inhibitors in First-Line Advanced NSCLC
Clinical Considerations in the Use of Checkpoint Inhibitors Breast Cancer.
TGF-β Inhibition and Immunotherapy: Checkmate
Tumor Immunology Ali Al Khader, MD Faculty of Medicine
PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. PD1 targeting alters the recruitment of immune cells to MC38 CRC tumors. MC38.
MSI.
Current Status of Biomarkers for Immune Checkpoint Inhibitors
Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell depletion. Analysis of tumor-infiltrating CD8+ T cells and effect of T and NK cell.
Combining Immunotherapy and Chemotherapy in NSCLC
The Nurse View.
Molecular Therapy - Oncolytics
Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.
Mice immunized twice with RRBC showed superior protection to tumor challenge with αGal-positive MC38 colon carcinoma cells compared with mock-immunized.
Increased CCL5 expression, infiltration of Treg cells, and apoptosis of CD8+ T cells in human colorectal tissues. Increased CCL5 expression, infiltration.
A, Proportion of variants detected in the MMR genes.
5FU-induced specific activation of CD8+ T cells.
Immunophenotypic analysis of TILs in B16 and K1735 melanoma following combination therapy with antibodies targeting PS and PD-1. Immunophenotypic analysis.
CPI-444 enhances T-cell activation in MC38 tumors.
Tumor protection induced by therapeutic PLG vaccination in combination with blockade antibodies. Tumor protection induced by therapeutic PLG vaccination.
Anti–PD-1/PD-L1–mediated acquired resistance is dependent on CD38-generated adenosine in the tumor microenvironment. Anti–PD-1/PD-L1–mediated acquired.
Cell counts of immune infiltrate and expression of galectin-1 and galectin-3 in the short-, medium-, and long-term survival cohorts. Cell counts of immune.
Presentation transcript:

Strategies to Induce Immunogenicity in Microsatellite Stable Colorectal Cancer

Early studies evaluating role of immune infiltrate in colorectal cancer

Tumors with high CD45RO+ associated with absence of lymphovascular and perineural invasion

Longer OS and DFS among patients with high density CD45RO+ cells

CD8+ and CD45+ cell densities predict OS and DFS in CRC

Does Immune Therapy Work in Colorectal Cancer?

PD-1 Blockade is Effective in MMR-D Colorectal Cancer

PD-1 Blockade significantly improves OS and PFS in MMR-D CRC compared to MMR-P CRC

Total somatic mutations per tumor in MMR-D v MMR-P tumors

Increased density of CD8+ T cells in tumor and invasive front in MMR-D cohort

Increased density of PD-L1 expression and CD8 T cells in tumor and invasive front in MMR-D cohort

PD-1 Blockade alone is ineffective in MMR-P CRC

Reasons for lack of response in MSS colon cancer

How do we make CRC make more “immunogenic”

Ad-CEA Vaccine

ETBX-011: Phase 1/2 Clinical Trial in Colorectal Cancer

Preclinical Model: MC38 C57BL/6 mice

Combination of MSB0010718C with 5-FU and Oxaliplatin

Treatment Schema

Endpoints and Statistical considerations

Future Directions

Acknowledgements

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2025 SlidePlayer.com. Inc. All rights reserved.